Decreased damage from transient focal cerebral ischemia by transfusion of zero-link hemoglobin polymers in mouse

Stroke

Volumn 40, Issue 1, 2009, Pages 278-284

  Mito, Toshiaki ^a   Nemoto, Masaaki ^a   Kwansa, Herman ^a   Sampei, Kenji ^a   Habeeb, Murtuza ^a   Murphy, Stephanie J ^b   Bucci, Enrico ^c   Koehler, Raymond C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Blood substitutes; Cerebral blood flow; Hemoglobin based oxygen carrier; Middle cerebral artery occlusion; Stroke

Indexed keywords

ALBUMIN; POLYMERIZED HEMOGLOBIN; HEMOGLOBIN; NEUROPROTECTIVE AGENT; OXYGEN; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD FLOW; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN SIZE; CONTROLLED STUDY; CROSS LINKING; EXCHANGE BLOOD TRANSFUSION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NONHUMAN; OXYGEN AFFINITY; PRIORITY JOURNAL; TRANSIENT ISCHEMIC ATTACK; ANIMAL; BLOOD BRAIN BARRIER; BLOOD COMPONENT THERAPY; BLOOD FLOW; BRAIN ARTERY; BRAIN CIRCULATION; C57BL MOUSE; CATTLE; CEREBRAL ARTERY DISEASE; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; METABOLISM; METHODOLOGY; MOLECULAR WEIGHT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPLANCHNIC BLOOD FLOW; TREATMENT OUTCOME; VASOCONSTRICTION;

ANIMALS; BLOOD COMPONENT TRANSFUSION; BLOOD-BRAIN BARRIER; BRAIN INFARCTION; CATTLE; CEREBRAL ARTERIES; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMOGLOBINS; INFARCTION, MIDDLE CEREBRAL ARTERY; ISCHEMIC ATTACK, TRANSIENT; MALE; MICE; MICE, INBRED C57BL; MOLECULAR WEIGHT; NEUROPROTECTIVE AGENTS; OXYGEN; POLYMERS; REGIONAL BLOOD FLOW; SPLANCHNIC CIRCULATION; TREATMENT OUTCOME; VASOCONSTRICTION;

EID: 60549095846     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.526731     Document Type: Article

References (30)

1. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in acute ischemic stroke. Stroke. 1988;19:464-471.
2. The Hemodilution in Stroke Study Group. Hypervolemic hemodilution treatment of acute stroke. Results of a randomized multicenter trial using pentastarch. Stroke. 1989;20:317-323.
3. Goslinga H, Eijzenbach V, Heuvelmans JHA, Laan de Vries E, Melis VMJ, Schmid-Schonbein H, Bezemer PD. Custom-tailored hemodilution with albumin and crystalloids in acute ischemic stroke. Stroke. 1992;23: 181-188.
4. Koller M, Haenny P, Hess K, Weniger D, Zangger P. Adjusted hypervolemic hemodilution in acute ischemic stroke. Stroke. 1990;21: 1429-1434.
5. Cole DJ, Drummond JC, Patel PM, Nary JC, Applegate RL. Effect of oncotic pressure of diaspirin crosslinked hemoglobin (DCLHb) on brain injury after temporary focal cerebral ischemia in rats. Anesth Analg. 1996;83:342-347.
6. Cole DJ, Drummond JC, Patel PM, Reynolds LR. Hypervolemichemodilution during cerebral ischemia in rats: effect of diaspirin crosslinked hemoglobin (DCLHb) on neurologic outcome and infarct volume. J Neurosurg Anesthesiol. 1997;9:44-50.
7. Saxena R, Wijnhoud AD, Carton H, Hacke W, Kaste M, Przybelski RJ, Stern KN, Koudstaal PJ. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke. 1999;30: 993-996.
8. Saxena R, Wijnhoud AD, Man in 't Veld AJ, van den Meiracker AH, Boomsma F, Przybelski RJ, Koudstaal PJ. Effect of diaspirin crosslinked hemoglobin on endothelin-1 and blood pressure in acute ischemic stroke in man. J Hypertens. 1998;16:1459-1465.
9. Gulati A, Singh G, Rebello S, Sharma AC. Effect of diaspirin crosslinked and stroma-reduced hemoglobin on mean arterial pressure and endothelin-1 concentration in rats. Life Sci. 1995;56:1433-1442.
10. Gulati A, Sharma AC, Singh G. Role of endothelin in the cardiovascular effects of diaspirin crosslinked hemoglobin. Crit Care Med. 1996;24: 137-147.
11. Sampei K, Ulatowski JA, Asano Y, Kwansa H, Bucci E, Koehler RC. Role of nitric oxide scavenging in vascular response to cell-free hemoglobin transfusion. Am J Physiol Heart Circ Physiol. 2005;289: H1191-H1201.
12. Kawaguchi AT, Fukumoto D, Haida M, Ogata Y, Yamano M, Tsukada H. Liposome-encapsulated hemoglobin reduces the size of cerebral infarction in the rat: evaluation with photochemically induced thrombosis of the middle cerebral artery. Stroke. 2007;38:1626-1632.
13. Tsai AG, Vandegriff KD, Intaglietta M, Winslow RM. Targeted O2 delivery by low-P50 hemoglobin: a new basis for O2 therapeutics. Am J Physiol Heart Circ Physiol. 2003;285:H1411-H1419.
14. Gould SA, Moore EE, Hoyt DB, Ness PM, Norris EJ, Carson JL, Hides GA, Freeman IH, DeWoskin R, Moss GS. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. J Am Coll Surg. 2002;195:445-452.
15. Kasper SM, Walter M, Grune F, Bischoff A, Erasmi H, Buzello W. Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg. 1996;83: 921-927.
16. Bobofchak KM, Mito T, Texel SJ, Bellelli A, Nemoto M, Traystman RJ, Koehler RC, Brinigar WS, Fronticelli C. A recombinant polymeric hemoglobin with conformational, functional, and physiological characteristics of an in vivo O2 transporter. Am J Physiol Heart Circ Physiol. 2003; 285:H549-H561.
17. Nemoto M, Mito T, Brinigar WS, Fronticelli C, Koehler RC. Salvage of focal cerebral ischemic damage by transfusion of high O2-affinity recombinant hemoglobin polymers in mouse. J Appl Physiol. 2006;100: 1688-1691.
18. Matheson B, Kwansa HE, Bucci E, Rebel A, Koehler RC. Vascular response to infusions of a nonextravasating hemoglobin polymer. J Appl Physiol. 2002;93:1479-1486.
19. Bucci E, Razynska A, Kwansa H, Matheson-Urbaitis B, O'Hearne M, Ulatowski JA, Koehler RC. Production and characteristics of an infusible oxygen-carrying fluid based on hemoglobin intramolecularly crosslinked with sebacic acid. J Lab Clin Med. 1996;128:146-153.
20. Goto S, Sampei K, Alkayed NJ, Doré S, Koehler RC. Characterization of a new double-filament model of focal cerebral ischemia in heme oxygenase-2-deficient mice. Am J Physiol Regul Integr Comp Physiol. 2003; 285:R222-R230.
21. Hughes GS, Antal EJ, Locker PK, Francom SF, Adams WJ, Jacobs EE Jr. Physiology and pharmacokinetics of a novel hemoglobin-based oxygen carrier in humans. Crit Care Clin. 1996;24:756-764.
22. Bjorkholm M, Fagrell B, Przybelski R, Winslow N, Young M, Winslow RM. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol. Haematologica. 2005;90:505-515.
23. Rebel A, Ulatowski JA, Kwansa H, Bucci E, Koehler RC. Cerebrovascular response to decreased hematocrit: effect of cell-free hemoglobin, plasma viscosity, and CO2. Am J Physiol Heart Circ Physiol. 2003;285: H1600-H1608.
24. Qin X, Kwansa H, Bucci E, Roman RJ, Koehler RC. Role of 20-HETE in the pial arteriolar constrictor response to decreased hematocrit after exchange transfusion of cell-free polymeric hemoglobin. J Appl Physiol. 2006;100:336-342.
25. Vadapalli A, Goldman D, Popel AS. Calculations of oxygen transport by red blood cells and hemoglobin solutions in capillaries. Artif Cells Blood Substit Immobil Biotechnol. 2002;30:157-188.
26. McCarthy MR, Vandegriff KD, Winslow RM. The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: implications for the design of hemoglobin-based oxygen carriers. Biophys Chem. 2001; 92:103-117.
27. Page TC, Light WR, McKay CB, Hellums JD. Oxygen transport by erythrocyte/hemoglobin solution mixtures in an in vitro capillary as a model of hemoglobin-based oxygen carrier performance. Microvasc Res. 1998;55:54-64.
28. Rebel A, Ulatowski JA, Joung K, Bucci E, Traystman RJ, Koehler RC. Regional cerebral blood flow in cats with crosslinked hemoglobin transfusion during focal cerebral ischemia. Am J Physiol Heart Circ Physiol. 2002;282:H832-H841.
29. Ulatowski JA, Nishikawa T, Matheson-Urbaitis B, Bucci E, Traystman RJ, Koehler RC. Regional blood flow alterations after bovine fumaryl ββ-crosslinked hemoglobin transfusion and nitric oxide synthase inhibition. Crit Care Med. 1996;24:558-565.
30. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30:2752-2758.